Xoft, a developer of Electronic Brachytherapy systems based upon miniaturized X-ray tube technology, has presented the clinical benefits of Axxent Electronic Brachytherapy (eBx) system from the 14 studies at American Association of Physicists in Medicine Meeting (AAPM).
Xoft said that the eBx system, used for single-dose Intraoperative radiation therapy (IORT), offers safe, convenient alternative to traditional therapy across broad range of cancers.
Xoft added that several studies continue to demonstrate the ability of Electronic Brachytherapy to deliver equivalent treatment results to traditional isotopic therapies with reduced exposure to surrounding healthy tissues and other studies validate its safety and performance.
Another series of studies explored extending the utilisation of Electronic Brachytherapy with new applications to the treatment of breast and other cancers, including skin and endocavitary cancer.
According to Xoft, researchers from Washington University in St Louis have evaluated the ability of Electronic Brachytherapy to serve as an alternative for the treatment of early stage rectal carcinoma in the study, entitled ‘A New Technique for Endocavitary Radiotherapy: Treatment with an Electronic Brachytherapy Source.’
The results of the dosimetric comparison between the historically used Philips RT-50 (papillon technique) and the Xoft Axxent System were also presented.
The study entitled ‘Comparison of Tumor and Normal Tissue Dose for Accelerated Partial Breast Irradiation Using an Electronic Brachytherapy eBx Source and Iridium-192 Source,’ compared treatment plans for patients treated with eBx using the Axxent System as adjuvant therapy for early stage breast cancer, with treatment plans prepared from the same CT image sets using an Iridium-192 (Ir-192) source.
According to the study, the results demonstrated that both forms of balloon-based brachytherapy provide comparable dose to the planning target volume (PTV).
Michael Klein, president and CEO of Xoft, said: “Building on several recent publications validating IORT using Electronic Brachytherapy, the 14 AAPM presentations further expand the body of research supporting the safety and efficacy of the Axxent System across a wide range of cancers.
“The AAPM presentations demonstrate that the isotope-free cancer treatment platform is safe, convenient alternative to deliver IORT for breast and other cancers that is professionally validated and patient friendly.”